Baird Medical Celebrates 2024 Breakthroughs and Accolades, Forging a New Era in Minimally Invasive MWA Technology
Baird Medical Investment Holdings (NASDAQ: BDMD) marked a transformative year in 2024, highlighted by its successful Nasdaq listing on October 2. The company, specializing in Microwave Ablation (MWA) technology, secured multiple patents enhancing MWA technology and production efficiency.
Key achievements include obtaining a Class III Medical Device Production License in China and receiving notable industry recognition, including designation as a Jiangsu Province High-Tech Enterprise. The company's subsidiary, Nanjing Great Wall, strengthened its position with four new patents focused on vascular thermal coagulation and RF ablation catheter optimization.
Nanjing Great Wall also secured a Class III Medical Device Registration Certificate in China for its Disposable Microwave Ablation Needle and obtained ISO 13485 certification, enhancing its international market access. These developments position Baird Medical for continued global expansion and advancement in minimally invasive treatment solutions.
Baird Medical Investment Holdings (NASDAQ: BDMD) ha segnato un anno trasformativo nel 2024, culminato con il suo successo nella quotazione Nasdaq il 2 ottobre. L'azienda, specializzata nella tecnologia di Ablazione a Microonde (MWA), ha ottenuto diversi brevetti che migliorano la tecnologia MWA e l'efficienza produttiva.
I risultati chiave includono l'ottenimento di una licenza di produzione di Dispositivi Medici di Classe III in Cina e il riconoscimento notevole nell'industria, inclusa la designazione come Impresa High-Tech della Provincia di Jiangsu. La controllata dell'azienda, Nanjing Great Wall, ha rafforzato la sua posizione con quattro nuovi brevetti focalizzati sulla coagulazione termica vascolare e sull'ottimizzazione dei cateteri per ablazione RF.
Nanjing Great Wall ha inoltre ottenuto un certificato di registrazione di Dispositivo Medico di Classe III in Cina per il suo Ago per Ablazione a Microonde Usa e Getta e ha conseguito la certificazione ISO 13485, migliorando l'accesso al mercato internazionale. Questi sviluppi pongono Baird Medical in una posizione favorevole per un'ulteriore espansione globale e avanzamenti nelle soluzioni di trattamento mininvasivo.
Baird Medical Investment Holdings (NASDAQ: BDMD) marcó un año transformador en 2024, destacado por su exitosa cotización en Nasdaq el 2 de octubre. La empresa, especializada en tecnología de Ablación por Microondas (MWA), aseguró múltiples patentes que mejoran la tecnología MWA y la eficiencia de producción.
Los logros clave incluyen la obtención de una licencia de producción de Dispositivos Médicos de Clase III en China y el reconocimiento notable en la industria, incluyendo la designación como Empresa de Alta Tecnología de la Provincia de Jiangsu. La subsidiaria de la empresa, Nanjing Great Wall, fortaleció su posición con cuatro nuevas patentes centradas en la coagulación térmica vascular y la optimización del catéter de ablación por RF.
Nanjing Great Wall también obtuvo un certificado de registro de Dispositivo Médico de Clase III en China para su Aguja desechable de Ablación por Microondas y logró la certificación ISO 13485, mejorando su acceso al mercado internacional. Estos desarrollos posicionan a Baird Medical para una continua expansión global y avances en soluciones de tratamiento mínimamente invasivas.
베어드 메디컬 투자 홀딩스 (NASDAQ: BDMD)는 2024년에 전환적 해를 맞이했으며, 10월 2일 나스닥 상장으로 그 성과를 자랑했습니다. 이 회사는 마이크로파 절제 기술(MWA)에 전문화되어 있으며, MWA 기술 및 생산 효율성을 향상시키는 여러 특허를 확보했습니다.
주요 성과로는 중국에서의 III급 의료 기기 생산 라이센스 획득과 더불어, 장쑤성 고기술 기업으로 지정된 것을 포함한 업계의 주목받는 인정을 받았습니다. 이 회사의 자회사인 난징 그레이트 월는 혈관 열 응고 및 RF 절제 카테터 최적화를 중심으로 한 4개의 신규 특허로 그 입지를 강화했습니다.
난징 그레이트 월은 또한 중국에서 일회용 마이크로파 절제 바늘에 대한 III급 의료 기기 등록 인증서를 확보하고, ISO 13485 인증을 받아 국제 시장 접근성을 높였습니다. 이러한 발전은 베어드 메디컬이 계속해서 글로벌 확장 및 최소 침습 치료 솔루션의 발전을 도모할 수 있는 기반이 됩니다.
Baird Medical Investment Holdings (NASDAQ: BDMD) a marqué une année transformative en 2024, mise en avant par son inscription réussie sur le Nasdaq le 2 octobre. L'entreprise, spécialisée dans la technologie d'Ablation par Micro-ondes (MWA), a obtenu plusieurs brevets améliorant la technologie MWA et l'efficacité de production.
Parmi les réalisations clés, on note l'obtention d'une licence de production de Dispositifs Médicaux de Classe III en Chine et la reconnaissance notable dans l'industrie, y compris la désignation en tant qu'Entreprise High-Tech de la Province du Jiangsu. La filiale de l'entreprise, Nanjing Great Wall, a renforcé sa position avec quatre nouveaux brevets axés sur la coagulation thermique vasculaire et l'optimisation des cathéters d'ablation par RF.
Nanjing Great Wall a également obtenu un certificat d'enregistrement de Dispositif Médical de Classe III en Chine pour son Aiguille d'Ablation par Micro-ondes Jetable et a obtenu la certification ISO 13485, améliorant ainsi son accès au marché international. Ces développements positionnent Baird Medical pour une expansion mondiale continue et des avancées dans les solutions de traitement mini-invasives.
Baird Medical Investment Holdings (NASDAQ: BDMD) erlebte im Jahr 2024 ein transformative Jahr, das am 2. Oktober mit einem erfolgreichen Nasdaq-Listing gekrönt wurde. Das Unternehmen, das auf Microwave Ablation (MWA) Technologie spezialisiert ist, sicherte sich mehrere Patente, die die MWA-Technologie und die Produktionseffizienz verbessern.
Zu den wichtigsten Erfolgen gehört der Erhalt einer Produktlizenz für medizinische Geräte der Klasse III in China und die Anerkennung in der Branche, darunter die Auszeichnung als High-Tech-Unternehmen der Provinz Jiangsu. Die Tochtergesellschaft des Unternehmens, Nanjing Great Wall, stärkte ihre Position mit vier neuen Patenten, die sich auf die vaskuläre Wärmekoagulation und die Optimierung von RF-Ablationskathetern konzentrieren.
Nanjing Great Wall erhielt auch ein Registrierungszertifikat für medizinische Geräte der Klasse III in China für ihre Einweg-Mikrowellenablationsnadel und erhielt die ISO 13485-Zertifizierung, wodurch der internationale Marktzugang erweitert wurde. Diese Entwicklungen positionieren Baird Medical für eine fortgesetzte globale Expansion und Fortschritte in minimalinvasiven Behandlungslösungen.
- None.
- None.
Nasdaq Listing
On October 2, 2024 (
Patents
In 2024, Baird Medical further expanded its intellectual property portfolio, securing patents that enhance MWA technology and production efficiency:
- Invention Patent: Semi-rigid Penetrating Microwave Ablation Antenna, Transmission Line Structure, and Assembly Method
- Invention Patent: Assembly Method and Transmission Line Structure for a Semi-flexible Microwave Ablation Antenna
- Utility Model Patent: Automated Drying Device
These patents center on the design and assembly of microwave ablation antennas, as well as the application of automated drying technology—advancements that showcase the Company's leadership in refining MWA solutions.
Class III Medical Device Production License in
The Company obtained a Class III Medical Device Production License in
Industry Recognition & Awards
Baird Medical's relentless focus on R&D and commercialization has been recognized through several prestigious industry honors, reinforcing its impact in oncology treatment and medical innovation.
- 2024 Suzhou Engineering Technology Research Center (Suzhou Tumor Microwave Ablation Treatment System Engineering Technology Research Center)
- Jiangsu Province High-Tech Enterprise
- "Most Investment Value Award" at the 10th China Medical Industry Innovation Competition
Nanjing Great Wall: A Subsidiary Driving Medical Innovation
As a subsidiary of Baird Medical Investment Holdings Ltd., Nanjing Great Wall further cemented its position in minimally invasive treatments with four newly granted patents, focused on vascular thermal coagulation, RF ablation catheter optimization, and advanced MWA needle designs:
Patents
- Invention Patents
- Semi-rigid Endovascular Microwave Thermal Coagulation Antenna
- Adjustable-Bending Radiofrequency Ablation Catheter and Its Operating Method
- Utility Model Patents
- Microwave Ablation Needle with Drilling Functions
- Microwave Ablation Probe
Class III Medical Device Registration Certificate in
Nanjing Great Wall secured a Class III Medical Device Registration Certificate in
ISO 13485 Certification
To enhance international market accessibility, Nanjing Great Wall successfully obtained ISO 13485 certification, demonstrating its commitment to stringent global quality management standards for medical devices.
For Baird Medical and its subsidiaries, 2024 was a year defined by innovation, recognition, and growth. Building on these achievements, Baird Medical is poised to accelerate global expansion, deepen its investment in next-generation ablation technology, and strengthen collaborations with leading healthcare institutions. As the Company continues to push the boundaries of minimally invasive treatment, its focus remains on improving patient outcomes worldwide.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-celebrates-2024-breakthroughs-and-accolades-forging-a-new-era-in-minimally-invasive-mwa-technology-302360560.html
SOURCE BDMD
FAQ
When did Baird Medical (BDMD) get listed on Nasdaq?
What major patents did BDMD secure in 2024?
What significant certifications did BDMD receive in China during 2024?
What key industry awards did BDMD win in 2024?
What international certification did BDMD's subsidiary Nanjing Great Wall obtain in 2024?
